Drugs Made In Stock Today
| DMII Stock | 10.00 0.01 0.10% |
PerformanceGood
| Odds Of DistressLow
|
Drugs Made is trading at 10.00 as of the 10th of February 2026. This is a 0.10 percent up since the beginning of the trading day. The stock's open price was 9.99. Drugs Made has only a 7 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 12th of November 2025 and ending today, the 10th of February 2026. Click here to learn more.
Business Domain Financial Services | IPO Date 3rd of December 2025 | Classification Financials |
Drugs Made is entity of United States. It is traded as Stock on NASDAQ exchange. More on Drugs Made In
Moving against Drugs Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Drugs Stock Highlights
| CEO Board | Lynn Stockwell |
| Business Concentration | Diversified Capital Markets, Financial Services, NASDAQ Composite, Financials, Capital Markets, Financial Services, Financial Services (View all Sectors) |
| Financial Strength | |
Drugs Made In (DMII) is traded on NASDAQ Exchange in USA and employs 1 people. Drugs Made is listed under Diversified Capital Markets category by Fama And French industry classification. The company conducts business under Capital Markets sector and is part of Financials industry.
Check Drugs Made Probability Of Bankruptcy
Drugs Made In Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Drugs Made market risk premium is the additional return an investor will receive from holding Drugs Made long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0987 | |||
| Jensen Alpha | 0.0193 | |||
| Total Risk Alpha | 1.0E-4 | |||
| Sortino Ratio | (0.42) |
Drugs Stock Against Markets
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Drugs Made In. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is there potential for Diversified Capital Markets market expansion? Will Drugs introduce new products? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Drugs Made listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Drugs Made In's market price often diverges from its book value, the accounting figure shown on Drugs's balance sheet. Smart investors calculate Drugs Made's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Drugs Made's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Drugs Made's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.